What is RevMedx?
RevMedx operates at the intersection of advanced medical engineering and tactical casualty care. The company is best known for its proprietary XSTAT technology, a rapid-action hemostatic device designed to treat life-threatening bleeding in high-stakes environments. By providing solutions that are currently utilized by U.S. Special Operations Forces and endorsed by the Committee on Tactical Combat Casualty Care, RevMedx has established a robust market presence. Their product portfolio, which spans both prescription and over-the-counter medical supplies, addresses a critical gap in pre-hospital trauma management, ensuring that first responders have access to reliable, field-tested hemorrhage control tools.
How much funding has RevMedx raised?
RevMedx has raised a total of $3.7M across 2 funding rounds:
Series A
$3.5M
Debt
$150K
Series A (2016): $3.5M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Key Investors in RevMedx
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed investor participating in the early-stage capital formation to support initial product development.
Undisclosed Investor
An undisclosed investor providing strategic backing to facilitate the commercialization of tactical medical devices.
What's next for RevMedx?
With the recent capital injection, RevMedx is well-positioned to scale its manufacturing capabilities and expand its reach within the civilian emergency medical services market. The strategic focus will likely center on broadening the adoption of its hemorrhage control solutions, potentially diversifying its product pipeline to address a wider array of trauma-related injuries. As the company transitions into this next phase of growth, the emphasis will remain on maintaining the high standards of efficacy required by tactical medical professionals while navigating the complexities of global medical device distribution and regulatory compliance.
See full RevMedx company page
